Hsp70 inducer, 17-allylamino-demethoxygeldanamycin, provides neuroprotection via anti-inflammatory effects in a rat model of traumatic brain injury

YOUQUAN GU1, JUN CHEN2, TIANHONG WANG2, CHAONING ZHOU1, ZHAODONG LIU1 and LANHUA MA1

1Department of Neurology, Donggang Branch of The First Hospital of Lanzhou University; 2Department of Neurology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China

Received October 15, 2015; Accepted April 4, 2016

DOI: 10.3892/etm.2016.3821

Abstract. Traumatic brain injury (TBI) is the predominant cause of mortality in young adults and children living in China. TBI induces inflammatory responses; in addition, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6 are important pro-inflammatory cytokines. Considering the observation that Hsp-70 overexpression can exert neuroprotection, identifying a drug that is able to induce the upregulation of Hsp70 has the potential to be a promising therapy for the treatment of neurological diseases. Thus, the present study assessed the clinical effectiveness of an anticancer drug and Hsp70 activator, 17-allylamino-demethoxygeldanamycin (17-AAG), to evaluate its potential as a treatment for patients with TBI. The aim of present study was to determine the neuroprotective effects of 17-AAG following trauma and to investigate the underlying mechanisms of action. To establish rat models, rats were subjected to a controlled cortical impact injury and randomly divided into vehicle or 17-AAG groups. In the 17-AAG group, rats were administered with an intraperitoneal injection of 17-AAG (80 mg/kg) immediately following the establishment of TBI. The motor function was measured using Neurologic Severity Score, and neuronal death was evaluated using immunofluorescence. The expression levels of GLT-1, Bcl-2 and Hsp-70 were detected by western blot analysis and the expression levels of inflammatory cytokines were quantified using ELISA. The present study determined that 17-AAG significantly reduced brain edema and motor neurological deficits (P<0.05), in addition to increasing neuronal survival. The aforementioned findings are associated with a downregulation of the expression levels of pro-inflammatory cytokines TNF-α, IL-1β and IL-6. Conversely, no significant changes of glutamate transporter-1 expression were observed. The present results suggest that 17-AAG treatment may provide a neuroprotective effect by reducing inflammation following TBI.

Introduction

Traumatic brain injury (TBI) is the leading cause of mortality in young adults and children living in China (1). Head trauma has numerous consequences in the brain, including axonal damage, microvascular alterations and blood-brain barrier disruption (2). The aforementioned outcomes are a result of both primary and secondary mechanisms following injury (3). Primary damage is a result of mechanical factors occurring immediately following trauma. Conversely, the fundamental mechanisms underlying secondary damage in TBI include inflammation, oxygen free radicals, brain edema formation and neuronal apoptosis (4). In particular, previous studies have demonstrated that tumor necrosis factor-α (TNF-α), interleukin (IL)-1β and IL-6 are crucial pro-inflammatory cytokines following trauma (5-7). Although the potential effects of TNF-α, IL-1β and IL-6 in human patients with TBI have yet to be elucidated, evidence from animal models has revealed that upregulated expression levels of the aforementioned cytokines are harmful, whereas their attenuation may alleviate tissue damage as well as brain edema, thereby improving the functional outcomes of patients with TBI (8).

Heat shock protein 70 (Hsp70; 72 kDa) is a highly stress-inducible member of a chaperone family of proteins (9). Previous studies in focal and global cerebral ischemia models have revealed that the overexpression of Hsp70 is protective against secondary damage in TBI, such as inflammation, oxygen free radicals and brain edema (10,11). Conversely, downregulated expression levels of Hsp70 resulted in a worse outcome in a rat model of stroke (12). Kim et al (13) demonstrated that Hsp70 contributed to the modulation of immune responses by potentiating or inhibiting them.
It is widely established that inflammation is capable of inducing brain tissue damage following TBI. Thus, the present study aimed to determine whether the Hsp70 activator, 17-allylamino-demethoxygeldanamycin (17-AAG), is able to upregulate the expression levels of Hsp70 in addition to reducing the expression levels of pro-inflammatory cytokines TNF-α, IL-1β and IL-6, in a rat model of TBI, as observed in neuroprotective processes.

Materials and methods

Animals and ethics statement. Male Sprague-Dawley rats (n=90; weight, 280-320 g) obtained from the Lanzhou University Experimental Animal Center (Lanzhou, China) were provided ad libitum access to food and water prior to surgery under optimal conditions (12-h light/dark cycle; 22˚C). All procedures were approved by the local legislation for ethics regarding experiments on animals (Ethics Committee of Lanzhou University, Lanzhou, China). The rats were anesthetized with sodium pentobarbital (Bio-Rad Laboratories, Inc., Shanghai, China) by intraperitoneal injection (50 mg/kg; Beijing, China).

Models of TBI. A previously described controlled cortical impact (CCI) injury procedure was utilized (14).

Groups and drug administration. Rats were randomly assigned to the vehicle group (n=30) or the 17-AAG group (n=30). The vehicle group received only equal volumes of 0.9% saline solution (20 mg/ml) and the 17-AAG group received 17-AAG dissolved in 0.9% saline that had been stored at 4˚C. Following the establishment of TBI, 17-AAG was immediately administered by a single intraperitoneal injection in the 17-AAG group (80 mg/kg body weight).

Evaluation of brain edema. Brain edema was evaluated by analysis of brain water content, as previously described (15).

Recovery of motor function. Motor function was evaluated as described previously (15). Neurologic Severity Score (NSS) was evaluated at 1, 3, 5 and 7 days (15).

Immunofluorescence. Rats were anesthetized with sodium pentobarbital (i.p.; 50 mg/kg; Beijing, China) prior to sacrifice. Coronal sections (10 µm) were obtained from the anterior area of the left hemisphere. Immunofluorescence was performed as described previously (15). Briefly, brain tissue samples were fixed by intracardiac perfusion with 0.1 mol/l PBS (pH 7.4). The brains were rapidly isolated. Coronal sections (10 µm) were obtained from the anterior area of the left hemisphere, washed with 0.1 M PBS, fixed in 10% formalin (Bio-Rad Laboratories, Inc.) for 24 h at room temperature, dehydrated in graded ethanol (70, 90, 95 and 100%), and embedded in paraffin (Bio-Rad Laboratories, Inc.). Tissue sections (6-mm thick) were incubated with an anti-Hsp70 antibody (diluted 1:500; Bio-rad Laboratories, Inc.) at 4˚C for 24 h. The tissue sections were then incubated with the relevant secondary antibodies for 90 min at room temperature. Slides were developed with diaminobenzidine substrate (Bio-Rad Laboratories, Inc.) and the images were captured using a microscope (BX41-P; Olympus Corp.).

Western blot analysis. Western blot analysis was performed as previously described (15). Briefly, rats were anesthetized and underwent intracardiac perfusion with 0.1 mol/l PBS (pH 7.4). The cortex region of the brains was rapidly isolated, homogenized (BestBio Biotechnology Co., Ltd., Shanghai, China), total proteins were extracted and protein concentration was determined using a Bicinchoninic Acid Protein Assay kit (Bio-Rad Laboratories, Inc.) according to the manufacturer's protocol. The protein samples were subjected to SDS-PAGE (Bio-Rad Laboratories, Inc). Protein concentration was determined using a bicinchoninic acid assay (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China). Total protein (35 µg) was separated by 12% SDS-PAGE gel electrophoresis (80 V for 30 min at 28˚C for spacer gel, and then 120 V for 1 h at 28˚C for separation gel) and transferred from the gel onto polyvinylidene fluoride membranes (Roche Diagnostics GmbH, Mannheim, Germany). The membranes were blocked with 5% non fat dry milk for 1 h at room temperature. Following blocking, the membranes were incubated with the following primary antibodies, all purchased from Santa Cruz Biotechnology, Inc., overnight at 4˚C: Rabbit anti-Hsp70 polyclonal antibody (diluted 1:500; cat no. sc-33575), rabbit anti-caspase-3 polyclonal antibodies diluted 1:500, rabbit anti-B-cell lymphoma 2 (Bcl-2) polyclonal antibody (diluted 1:500; cat no. sc-492), rabbit anti-glutamate transporter-1 (GLT-1) polyclonal antibody (diluted 1:500; cat no. sc-15317) and mouse anti-β-actin monoclonal antibody (diluted 1:500; cat no. sc-376421). Membranes were then washed twice with tris-buffered saline with Tween-20 (TBST) for 20 min. Subsequently, membranes were incubated with horseradish peroxidase conjugated anti-rabbit IgG (diluted 1:5,000; cat no. sc-2025) and anti-mouse IgG (diluted 1:5,000; cat no. sc-2025; both Santa Cruz Biotechnology, Inc.) for 2 h at room temperature. Membranes were washed four times with TBST for 40 min. The immunoblot on the membrane was visualized using an enhanced chemiluminescence detection system (ImageQuant EC; GE Healthcare Life Sciences, Tokyo, Japan). PBS was used in place of primary antibodies in the negative control group.

Immunohistochemistry. Rats were anesthetized and sacrificed by intracardiac perfusion with 0.1 mol/l PBS (pH 7.4). The brains were rapidly isolated. Coronal sections (10 µm) were obtained from the anterior area of the left hemisphere, washed with 0.1 M PBS, fixed in 10% formalin (Bio-Rad Laboratories, Inc.) for 24 h at room temperature, dehydrated in graded ethanol (70, 90, 95 and 100%), and embedded in paraffin (Bio-Rad Laboratories, Inc.). Tissue sections (6-mm thick) were incubated with an anti-Hsp70 antibody (diluted 1:500; Bio-rad Laboratories, Inc.) at 4˚C for 24 h. The tissue sections were then incubated with the relevant secondary antibodies for 90 min at room temperature. Slides were developed with diaminobenzidine substrate (Bio-Rad Laboratories, Inc.) and the images were captured using a microscope (BX41-P; Olympus Corp.).
Chalfont, UK) and densitometric signals were quantified using an imaging program (version 1.41; National Institutes of Health, Bethesda, MA, USA). Immunoreactive bands for all proteins were normalized to the corresponding bands for β-actin. The western blot results were analyzed with ImageJ Software (version 1.41; National Institutes of Health, Bethesda, MA, USA).

**Multiplex cytokine ELISA.** An immunosorbent assay was performed as described previously (16). The supernatant was then collected and total protein was determined by the Bradford method (16). The expression levels of inflammatory cytokines were quantified using ELISA kits specific for rats (cat no. 5000201; and Bio-Plex Pro™ Rat Cytokine 24-plex Assay cat no. 171K1001M; Bio-Rad Laboratories, Inc.) according to the manufacturer's protocol. The cytokine contents in the brain samples were expressed as picograms of antigen per milligram of protein.

**Statistical analysis.** All data are presented as means ± standard deviation. SPSS software (version 16.0; SPSS, Inc., Chicago, IL, USA) was used for the statistical analysis of all data. Statistical analysis was performed using one-way analysis of variance and followed by Student-Newman-Keuls post-hoc tests. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**17-AAG attenuates cerebral edema.** Brain edema suppresses cerebral perfusion pressure and oxygenation in the brain, resulting in an elevation in intracranial pressure following TBI (17). The formation of edema is an important factor to secondary injury following TBI. In the present study, the wet-dry weight method was used to evaluate cerebral edema at 1, 3, 5 and 7 days. As displayed in Fig. 1, the brain water content in the 17-AAG treatment group was significantly lower on days 1, 3 and 5 compared with the vehicle group (P<0.05).

**17-AAG attenuates motor deficits.** Recovery of motor deficits are expressed as ΔNSS in the present study. Fig. 2 revealed the changes in functional recovery at 1, 3, 5 and 7 days. It is evident that post-injury administration of 17-AAG significantly improved (P<0.05) the motor function recovery between 1 and 7 days following trauma compared with untreated rats.

**17-AAG increases neuronal survival in the cortex.** The cortex region of the brains was collected and immunostaining with the NeuN neuronal marker 24 h after TBI. Neuronal survival was quantified by counting the number of NeuN-positive cells in 1 mm of the rat cortex region. As presented in Fig. 3, 24 h after TBI treatment with 17-AAG significantly increased neuronal survival in the cortex region of the brain following trauma (P<0.05).

**17-AAG induces Hsp70 expression in the cortex.** The expression levels of Hsp70 in the cortex at the 24 h time-point were measured by immunohistochemistry and western blotting. As depicted in Fig. 4, administration of 17-AAG produced significant elevations in Hsp70 protein expression levels 24 h following TBI, as compared with the untreated group (P<0.05).

**17-AAG induces significant reductions in multiplex cytokine levels in the cortex.** The expression levels of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) in the cortex region of the rats were measured using commercially available ELISA kits at 24 h (Fig. 5). All three cytokine expression levels exhibited significant decreases following 17-AAG treatment compared with the vehicle group (P<0.05).

**17-AAG attenuates neuronal apoptosis death in the cortex.** The expression levels of caspase-3 and Bcl-2 in the cortex at 24 h were assessed by western blotting (Fig. 6). As demonstrated in Fig. 6, caspase-3 expression levels in the 17-AAG treatment group exhibited significant decreases compared with the vehicle group (P<0.05). Conversely Bcl-2 expression levels were significantly elevated (P<0.05). The present results indicate that 17-AAG treatment leads to the reduction of neuronal apoptosis in the cortex following TBI.

**17-AAG induces no significant changes in GLT-1 expression in the cortex of the brain.** The protein expression levels of GLT-1 in the cortex were analyzed by western blotting 24 h after TBI (Fig. 7). Treatment with 17-AAG induced no significant changes in GLT-1 expression compared with the vehicle group (P>0.05).

**Discussion**

TBI is the primary cause of mortality and disability in young adults living in China (18). In the present study, a CCI model of brain trauma was established. The advantages of a CCI model include the ability to control deformation parameters, such as depth and velocity of the impact (19). Additionally, this model is able to imitate the spectrum of diffuse axonal injury and focal-type damage observed in TBI (19). In the present study, any rats that did not display moderate to severe neurological deficits following the surgery were excluded from further investigations.

Hsps are a family of chaperones that control the synthesis, folding and degradation of proteins within cells (20). The Hsp family constitutes a major control system for protein quality. Previous studies have demonstrated that overexpression of chaperones may attenuate the formation of protein aggregates in transgenic mouse models, thus reducing oxidative stress levels in addition to enhancing the antioxidant activity of enzymes (20-23). Furthermore, studies have revealed that the overexpression of Hsp70 may exert neuroprotective effects in animal models of neurological diseases (22,23). As 17-AAG is an Hsp70 activator in vivo and displays limited hepatotoxicity (24), the present study hypothesized that 17-AAG may be a promising approach for the treatment of TBI. The results of the present study demonstrated that administration of 17-AAG immediately following TBI significantly reduced brain edema and motor neurological deficits, in addition to increasing neuronal survival. Furthermore, the aforementioned findings were associated with the downregulation of pro-inflammatory cytokines. Previous studies have demonstrated that 17-AAG provides neuroprotective effects in various animal models...
of neurological diseases, including neurodegenerative disorders, epilepsy, ischemia and acute brain injury (13,25). The results of the present study were concordant with those of the previous studies and consolidated upon previous evidence to demonstrate that post-injury treatment of 17-AAG provides neuroprotective properties through the attenuation of proinflammatory cytokines in a rat CCI model.

The inflammatory response induced following TBI is an important therapeutic target for reducing tissue damage following trauma (26). Additionally, it is a major contributing factor to secondary injury in TBI (26). A previous investigation revealed that when Hsp70 is overexpressed, the expression levels of the inducible isoform of nitric oxide synthase are reduced in astrocytes, whereas NF-κB is activated (27). Furthermore, in an in vitro study, Hsp70 prevented the lipopolysaccharide-induced upregulation of proinflammatory cytokines (28). Additionally, in a rat model of experimental stroke, overexpression of Hsp70 inhibited the production of IL-1β and TNF-α (29). The present study did not establish the existence of a direct association between TBI-induced functional deficits and pro-inflammatory factors, however, in vivo evidence that 17-AAG can provide a neuroprotective effect

Figure 1. Effect of 17-AAG treatment on brain edema. Brain water content was determined at 1, 3, 5 and 7 days following TBI. Error bars represent the mean ± standard error (n=5 per group). 17-AAG significantly decreased brain edema 1, 3 and 5 days following TBI (P<0.05, vs. the vehicle group). TBI, traumatic brain injury; 17-AAG, 17-allylamino-demethoxygeldanamycin.

Figure 2. Effect of 17-AAG treatment on traumatic brain injury-induced motor deficits. The temporal changes in motor recovery were determined at 1, 3, 5 and 7 days following TBI and calculated as ΔNSS. Error bars represent the mean ± standard error (n=5 per group). 17-AAG treatment significantly improved motor function at each time point (P<0.05, vs. the vehicle group). TBI, traumatic brain injury; 17-AAG, 17-allylamino-demethoxygeldanamycin; NSS, Neurologic Severity Score.

Figure 3. Neuronal survival was quantified using (A) Neuron-specific nuclear protein immunostaining in the cortex 24 h following traumatic brain injury. Magnification, x100. (B) Quantitative summary of the data reveals the number of surviving neurons/1 mm length of cortex sectors. Error bars are presented as means ± standard error (n=5 per group). The results demonstrate that administration of 17-AAG significantly increases neuronal survival in the cortex (P<0.05, vs. vehicle group). 17-AAG, 17-allylamino-demethoxygeldanamycin.

Figure 4. Effect of 17-AAG on Hsp70 expression levels following traumatic brain injury. (A) The immunohistochemistry images of Hsp70 in the vehicle and 17-AAG groups at 24 h. Magnification, x40. (B) Western blot analysis of the expression levels of Hsp70 in the cortex of the rats at 24 h. The quantitative results of Hsp70 were expressed as the ratio of densitometries of Hsp70 to β-actin bands. The error bars represent the mean ± standard error (n=5 per group). The results indicate significant upregulation of Hsp70 expression levels in the 17-AAG group (P<0.01, vs. the vehicle group). TBI, traumatic brain injury; 17-AAG, 17-allylamino-demethoxygeldanamycin; HSP70, heat shock protein.
partly by inhibiting proinflammatory cytokine activation (8) has been demonstrated.

Excitotoxicity is another crucial process in nervous cell death following TBI (30). Astrocytes may protect against glutamate excitotoxicity via glutamate transporters, and GLT-1 is the most important glutamate transporter in the brains of rats (31). However, in the present study, no significant change in GLT-1 expression levels following post-TBI 17-AAG
treatment were observed. It was there hypothesized that the neuroprotective effect of 17-AAG is not associated with the regulation of GLT-1 protein expression.

In summary, the present study demonstrated that the administration of Hsp70 activator 17-AAG reduced brain edema and motor neurological deficits, in addition to increasing neuronal survival, in a rat model of TBI. Furthermore, 17-AAG reduced TNF-α, IL-1β and IL-6 protein expression levels. Conversely, no significant changes in GLT-1 expression levels were observed. The findings of the present study emphasize that 17-AAG provides neuroprotection via anti-inflammatory effects in a rat model of TBI.

References